A Phase 2A Trial of DT402 for Autism Spectrum Disorder | MicrobiomeTrials← Back to trialsNCT07303907
A Phase 2A Trial of DT402 for Autism Spectrum Disorder
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-12-03Est. Completion: 2027-08
Enrollment target: 20 participants Locations- Spectrum Neuroscience and Treatment Institute, New York, New York, United States
Other microbiome trials you might be interested in
Autism Spectrum Disorder
This is an 18 to 54 week study assessing the efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI16…
Clayton, AustraliaCompleted Mar 1, 2024
Autism Spectrum DisorderSibling Relations
The purpose of this study was to evaluate the effectiveness of a novel psychoeducational program for adult siblings of a…
Heraklion, GreeceCompleted Oct 30, 2024
Recruiting
AutismDepressedDepressed Mood
Autism spectrum disorder is characterized by differences in social communication/interaction and the presence of restric…
Stony Brook, United StatesEst. completion Sep 2027